CN106456615B - 抗病毒化合物、医药组合物及其使用方法 - Google Patents

抗病毒化合物、医药组合物及其使用方法 Download PDF

Info

Publication number
CN106456615B
CN106456615B CN201580024136.9A CN201580024136A CN106456615B CN 106456615 B CN106456615 B CN 106456615B CN 201580024136 A CN201580024136 A CN 201580024136A CN 106456615 B CN106456615 B CN 106456615B
Authority
CN
China
Prior art keywords
virus
compound
compounds
viral
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580024136.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456615A (zh
Inventor
S·P·艾度纳托
K·M·贝达德
K·W·佛勒
I·马杜
S·凯瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of CN106456615A publication Critical patent/CN106456615A/zh
Application granted granted Critical
Publication of CN106456615B publication Critical patent/CN106456615B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580024136.9A 2014-05-09 2015-05-08 抗病毒化合物、医药组合物及其使用方法 Expired - Fee Related CN106456615B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
CN106456615A CN106456615A (zh) 2017-02-22
CN106456615B true CN106456615B (zh) 2020-10-27

Family

ID=54393071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024136.9A Expired - Fee Related CN106456615B (zh) 2014-05-09 2015-05-08 抗病毒化合物、医药组合物及其使用方法

Country Status (9)

Country Link
US (3) US9884876B2 (enExample)
EP (1) EP3139920A4 (enExample)
JP (1) JP6419313B2 (enExample)
CN (1) CN106456615B (enExample)
AU (3) AU2015255714B2 (enExample)
CA (1) CA2948178A1 (enExample)
MX (2) MX2016014642A (enExample)
TW (1) TW201623265A (enExample)
WO (1) WO2015172099A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CA3051422A1 (en) * 2018-08-09 2020-02-09 Kineta, Inc. Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
JP2022506351A (ja) * 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
JP2022550454A (ja) * 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン Ｂ型肝炎ウイルス感染の治療のための組成物及び方法
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
IL297050A (en) 2020-04-04 2022-12-01 Pfizer Methods of treating the 2019 corona virus disease
WO2021205290A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and method of treating covid-19
CA3140164A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19
US12485157B2 (en) 2020-04-05 2025-12-02 Pfizer Inc. Method of treating COVID-19
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US20230372310A1 (en) * 2020-10-15 2023-11-23 Baden-Württemberg Stiftung Gmbh Flavi-Block: A Pan-Flavivirus Inhibitor
CN116897155A (zh) * 2021-02-24 2023-10-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的苯并噻唑基双环[1.1.1]戊烷衍生物
EP4314011A4 (en) * 2021-03-24 2025-01-01 Anavex Life Sciences Corp. PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
WO2024252327A1 (en) 2023-06-09 2024-12-12 Pfizer Inc. Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds
CN103547576A (zh) * 2011-05-19 2014-01-29 伊莱利利公司 杀寄生虫的二氢异噁唑化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
WO2009067613A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
CA2786314A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547576A (zh) * 2011-05-19 2014-01-29 伊莱利利公司 杀寄生虫的二氢异噁唑化合物
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RN 313404-26-1;Registry;《Database Registry》;20010110 *
RN 880390-03-4;Registry;《Database Registry》;20060414 *

Also Published As

Publication number Publication date
US20190002477A1 (en) 2019-01-03
AU2015255714A1 (en) 2016-10-20
EP3139920A1 (en) 2017-03-15
US20170057978A1 (en) 2017-03-02
TW201623265A (zh) 2016-07-01
JP6419313B2 (ja) 2018-11-07
MX2020005187A (es) 2020-08-20
US20200270274A1 (en) 2020-08-27
WO2015172099A1 (en) 2015-11-12
CN106456615A (zh) 2017-02-22
JP2017515901A (ja) 2017-06-15
CA2948178A1 (en) 2015-11-12
EP3139920A4 (en) 2017-11-01
AU2020204324A1 (en) 2020-07-16
MX2016014642A (es) 2017-05-25
AU2020201815A1 (en) 2020-04-02
US9884876B2 (en) 2018-02-06
AU2015255714B2 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CN106456615B (zh) 抗病毒化合物、医药组合物及其使用方法
US20160102099A1 (en) Anti-viral compounds
US20160122312A1 (en) Anti-viral compounds, pharmaceutical compositions and methods of use thereof
AU2017254812B2 (en) Anti-viral compounds
TW201625573A (zh) 色烯酮（ｃｈｒｏｍｅｎｏｎｅ）抗病毒化合物、醫藥組合物及其使用方法
US20150342932A1 (en) Anti-viral compounds
TW201629035A (zh) 抗病毒化合物、醫藥組合物及其使用方法
NZ622636B2 (en) Substituted benzothiazole compounds and their use in the treatment of viral infections
OA19256A (en) Anti-Viral Compounds.
HK1199029B (en) Anti-viral compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201027

Termination date: 20210508